

1-6 Maandagochtend 8.30–11.45 GYN (195 min)

8.30–8.40 — Opening Inge + Slides

Inleiding

Spreker	Onderwerp	Sessie	Titel
Ramez Eskander	Gynecologic Cancer	Oral Abstract Session	Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.
Matthew Powell	Gynecologic Cancer	Oral Abstract Session	Long-term survival rates and cure modeling with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) primary advanced or recurrent endometrial cancer in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial.
Xiaohua Wu	Gynecologic Cancer	Oral Abstract Session	A phase III CHIPO study of chiaranib plus weekly paclitaxel for platinum-resistant or refractory ovarian cancer.
Lucy Gilbert	Gynecologic Cancer	Oral Abstract Session	Overall survival subgroup analyses for prior taxane use in the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel versus nab-paclitaxel monotherapy in patients with platinum-resistant ovarian cancer (GOG-3073, ENGOT-ov72, APGOT-Ov10, LACOG-0223, and ANZGOG-2221/2023).

9.40–10.00 — Modereren Christa van Schaik

10.00–10.20 — Pauze

BLOKJE GLP1 EN DIEET

Inleiding

Spreker	Onderwerp	Sessie	Titel
Claudia Marchetti	Gynecologic Cancer	Rapid Oral Abstract	Effects of short-term fasting compared to free diet in ovarian cancer patients: Results from a two-arm pilot randomized trial.
Salman Jajja	Quality Care/Health Services Research	Oral Abstract Session	The association of GLP-1 receptor agonist use with survival and immune-related adverse events in patients receiving immune checkpoint inhibitors: A multi-institutional real-world analysis.



Jess Paulus	Quality Care/Health Services Research	Oral Abstract Session	GLP-1 receptor agonist utilization and survival outcomes in a large U.S. community oncology cohort.
Jennifer Ligibel	Symptom Science and Palliative Care	Rapid Oral Abstract	Effect of a weight loss intervention (WLI) on quality of life (QOL) and symptoms in women with breast cancer: Results from the Breast Cancer Weight Loss (BWEL) trial.

Discussie

Tot 11.05

Inleiding

Spreker	Onderwerp	Sessie	Titel
Mark Dickson	Special Sessions	Plenary Session	SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.

Discussant LBA2

15 minuten over

Invoegen educational Gyn aan bovenste blokje. Dan pauze en na pauze modereren Christa?
Antibody-Drug Conjugates and Other New Agents in Ovarian Cancer: Managing Toxicities

11.50 — Laatste fietsen en naar Merlijn

12.00 — Lunch

1-6 Maandagmiddag 13.45–17.15 (210 min) BORST LOCAL

Tijd	Spreker	Onderwerp	Titel
13.55	Kalijn Bol	Melanoma/Skin Cancers	Combination of vemurafenib with cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with nivolumab and ipilimumab (COWBOY).

14.05 — Inleiding

Spreker	Onderwerp	Sessie	Titel
Robert Stein	Breast Cancer—Local/Regional/Adjuvant	Abstract Session	First results from the OPTIMA phase III randomized non-inferiority trial of test-directed chemotherapy in patients with high clinical risk ER-positive HER2-negative early breast cancer.
Jana de Boniface	Breast Cancer—Local/Regional/Adjuvant	Abstract Session	node macrometastases: Overall survival and patient-reported arm morbidity from the randomized SENOMAC trial.
Zhi-Ming Shao	Breast Cancer—Local/Regional/Adjuvant	Oral Abstract Session	trastuzumab and pertuzumab plus docetaxel (THP) ± CB as neoadjuvant therapy for HER2-positive early or locally advanced breast cancer: A randomized, open-label, multicenter, phase 3 trial.
Javier Cortes	Breast Cancer—Local/Regional/Adjuvant	Oral Abstract Session	Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Final analysis results from the phase 3 KEYNOTE-522 study.

Discussie

15.10–15.25 — Pauze

Inleiding

Spreker	Onderwerp	Sessie	Titel
Peter Schmid	Breast Cancer—Local/Regional/Adjuvant	Oral Abstract Session	Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2- eBC) in the phase III lidERA BC clinical trial: Results by menopausal status.
Martine Piccart-Gebhart	Breast Cancer—Local/Regional/Adjuvant	Oral Abstract Session	From Genomic Testing to Systemic Therapy: Personalizing Adjuvant Treatment for HR+/HER2- Breast Cancer.
Yang Yang	Breast Cancer—Local/Regional/Adjuvant	Oral Abstract Session	Updated overall survival results from a randomized phase III trial of non-cross-resistant adjuvant chemotherapy plus endocrine therapy versus endocrine therapy alone in HR+/HER2-/lymph node-positive breast cancer with residual disease following neoadjuvant chemotherapy (NCT01019616).

Rita Nanda Breast Cancer

Educational Session Advances in Systemic Treatment of Metastatic Triple-Negative Breast Cancer.

Discussion

16.40-17.00 — Refereren Jolien